Polaris Pharmaceuticals-KY (6550) Announces Board Re-election at Annual General Meeting
NQ Score
50/100
AI Summary (NQ-processed)
Polaris Pharmaceuticals-KY (6550) announced on May 15, 115 (2026) that its 115th annual general meeting of shareholders resulted in the full re-election of its board of directors, including independent directors. This change is due to the expiration of the current term. The new board includes re-elected members such as Chen Xian-Zhe, who will continue as Chairman, and new appointments like Zhou Hong-Jie, who holds a PhD in Chemistry and Chemical Biology from Harvard University. Other new directors and independent directors were also elected. The previous term ran from September 26, 112 (2023) to June 11, 115 (2026).
AI analysis data is not yet available.
Frequently Asked Questions
- Q: What is the company code for Polaris Pharmaceuticals-KY?
- A: The company code is 6550.
- Q: When was the annual general meeting held?
- A: The annual general meeting was held on May 15, 115 (2026).
- Q: What was the main purpose of the shareholder meeting?
- A: The main purpose was the full re-election of directors, including independent directors, due to the expiration of their terms.
- Q: Who are some of the newly elected directors?
- A: Newly elected directors include Chen Xian-Zhe (also Chairman), Digital Capital Inc. (represented by Wei Shao-Jun), Mai Investment Co., Ltd. (represented by Cai Gao-Zhong), and Zhou Hong-Jie. New independent directors include Zhao Ying-Cheng, Zhang Yi-Fang, Zhang Zhi-Gang, and Di Shi-Jie.
- Q: What is the tenure of the previous board?
- A: The previous term was from September 26, 112 (2023) to June 11, 115 (2026).